Nirsevimab Might Top Maternal Vax for Infants' RSV Protection

(MedPage Today) — Infants given the monoclonal antibody nirsevimab (Beyfortus) to provide passive immunity against respiratory syncytial virus (RSV) had a lower rate of related hospitalizations and severe outcomes than those whose mothers got…

Source link : https://www.medpagetoday.com/pediatrics/rsv/119142

Author :

Publish date : 2025-12-22 20:50:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Nirsevimab Might Top Maternal Vax for Infants’ RSV Protection

Benzodiazepines Linked With Adverse Pregnancy Outcomes

Air Pollution Linked to Depression

Related Posts

Could AI Help Predict the Next Pandemic?

We must completely change the way we build homes to stay below 2°C

Serum Haptoglobin: A Prognostic Biomarker for Urticaria?

GLP-1 Drugs Tied to Lower CRC Risk and Better Outcomes

ED Mental Health Bundle Boosts Disability Support, Not FQOL

EU Fluoride Exposure Deemed Safe as Regulators Review Limits

Could AI Help Predict the Next Pandemic?

We must completely change the way we build homes to stay below 2°C

Serum Haptoglobin: A Prognostic Biomarker for Urticaria?

GLP-1 Drugs Tied to Lower CRC Risk and Better Outcomes

ED Mental Health Bundle Boosts Disability Support, Not FQOL

EU Fluoride Exposure Deemed Safe as Regulators Review Limits

Regional Anesthesia: Key to Better Postoperative Outcomes?

Sooner-than-expected climate impacts could cost the world trillions

Categories

Archives